ProCE Banner Activity

Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment

Slideset Download
Conference Coverage
In oligometastatic NSCLC without progression after first-line systemic therapy, local consolidative therapy significantly improved PFS without increasing toxicity.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals